USA flag logo/image

An Official Website of the United States Government

Primate Model for Pharmaceutical Development

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75712
Program Year/Program:
2007 / STTR
Agency Tracking Number:
HL082043
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
VASADE BIOSCIENCES, INC.
675 US Highway One North Brunswick, NJ 08902-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2007
Title: Primate Model for Pharmaceutical Development
Agency: HHS
Contract: 2R42HL082043-02
Award Amount: $776,051.00
 

Abstract:

DESCRIPTION (provided by applicant): Advances in molecular medicine and genomic research promise to produce exciting new strategies for the treatment of human diseases. One significant concern regarding preclinical research data is that the results may not be predictive of future clinical outcomes. Many differences in anatomy, physiology and pathological processes exist between animals and humans. The goal of our STTR proposal is to set up a novel preclinical research model in monkeys. This chronica lly instrumented, conscious monkey model will closely mimic the process of congestive heart failure observed in human patients, which is a leading cause of mortality and morbidity in the US. Clearly, this model will help not only to elucidate the mechanism s of the heart disease, but also will provide a system for the assessment of potential new interventions in man. Pharmacodynamic and pharmacokinetic studies, as well as safety and toxicology assessments also may be performed. The Phase I STTR proje ct proved the hypothesis that combined myocardial infarction (MI) with rapid ventricular pacing can induce chronic myocardial ischemia leading to end stage heart failure in instrumented, conscious monkeys. The Phase II study will further characterize this model, particularly regarding the phenomenon of myocardial remolding, and may lead to the identification of genes involved in cardiac cell survival and death. To achieve the phase II goals, the study will use state-of-art, physiological, genomic an d pathological experimental approaches in monkeys. This Phase II project will enable the new business venture, Vasade Biosciences, to provide a valuable commercial contract research service for the early preclinical needs of biotechnology and pharmaceutica l companies.

Principal Investigator:

Youtang Shen
9739729517
SHENY1@UMDNJ.EDU

Business Contact:

Stephen F. Vatner
support@vasadebiosciences.com
Small Business Information at Submission:

VASADE BIOSCIENCES, INC.
VASADE BIOSCIENCES, INC. 16 East 27th Street BARNEGAT LIGHT, NJ 08006

EIN/Tax ID: 320115288
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UMDNJ-NJMS
UMDNJ-SCHOOL OF PUBLIC HEALTH
PO BOX 2688
NEW BRUNSWICK, NJ 8903
RI Type: Nonprofit college or university